CVD ASSESS
Implementation Manual

Preventing cardiovascular disease (CVD) in primary health care: assessing essential interventions using routine data (CVD ASSESS)
Address requests about publications of the WHO Regional Office for Europe to:

Publications
WHO Regional Office for Europe
UN City, Marmoovej 51
DK-2100 Copenhagen Ø, Denmark

Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest).

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition: CVD ASSESS implementation manual: preventing cardiovascular disease (CVD) in primary health care: assessing essential interventions using routine data (CVD ASSESS). Copenhagen: WHO Regional Office for Europe; 2020”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. (http://www.wipo.int/amc/en/mediation/rules/)


Cataloguing-in-Publication (CIP) data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

1. Development of CVD ASSESS ............................................................................................................................................................................................... 1

   Purpose of CVD ASSESS .......................................................................................................................................................................................... 2

   Components and intended audience ........................................................................................................................................................................ 2

   Core indicators .................................................................................................................................................................................................. 2

2. How to implement CVD ASSESS .................................................................................................................................................................................. 4

   Human resources .................................................................................................................................................................................................. 5

   Establish a steering committee ........................................................................................................................................................................... 5

   Data collection .................................................................................................................................................................................................. 5

   Data analysis ...................................................................................................................................................................................................... 5

   Identify the public health goal ............................................................................................................................................................................. 5

   Establish a practice standard ........................................................................................................................................................................... 6

   Study design .................................................................................................................................................................................................. 6

   Population sample .............................................................................................................................................................................................. 7

   Determining the sample size ............................................................................................................................................................................ 8

   Project protocol .................................................................................................................................................................................................. 8

3. References ....................................................................................................................................................................................................... 10
Purpose of CVD ASSESS

The purpose of CVD ASSESS is to provide a free, open-source, standardized data collection method for use in resource-limited settings to assess essential CVD interventions in primary health care using routine clinical data.

CVD ASSESS was initially developed to measure the impact of implementing essential cardiovascular disease interventions in primary health care. It was designed for use in settings with a range of types of medical health record infrastructure (from paper-based records to electronic health records). It has been tested in low- and middle-income countries, including in health facilities with no Internet or mobile service coverage using paper-based data extraction forms. It has been used to extract data from nearly 10,000 paper-based patient records.

Components and intended audience

This implementation manual is intended for people working at the national level (such as a health ministry), and the contents of the CVD ASSESS package are relevant to those working at the subnational level (such as programme managers) and the primary health care level (such as data collectors, clinical statisticians and clinicians).

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementation guide (this document)</td>
<td>An overview of CVD ASSESS</td>
</tr>
<tr>
<td>Data Collection Training Module</td>
<td>Material to train data collectors</td>
</tr>
<tr>
<td>Data collection field guide</td>
<td>Important information and troubleshooting for data collectors</td>
</tr>
<tr>
<td>Data collection forms</td>
<td>Forms used to collect raw data from patient records: online, offline, and paper versions</td>
</tr>
</tbody>
</table>

Core indicators

Table 1 shows the list of core indicators and the questions they seek to address. An expanded table is available in the Annex that details the numerators and denominators in greater detail. Using CVD ASSESS will provide you with the necessary raw data to calculate the core indicators. In addition, you may wish to further analyse the raw data and develop subsequent indicators. We encourage that users at least report the core indicators so that performance can be compared with that of other countries that have also used CVD ASSESS and reported core indicators (1,2).

<table>
<thead>
<tr>
<th>Question</th>
<th>Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are CVD risk factors being measured?</td>
<td>Proportion of eligible patients who have all risk factor values recorded as required for calculating the risk score</td>
</tr>
<tr>
<td>Are CVD risk factor measurements being converted to a total risk score?</td>
<td>Proportion of patients aged 40 years or older who have visited in the past 12 months who have all measurements required for calculating the risk score within 12 months of the most recent date of visit and have a documented risk score</td>
</tr>
<tr>
<td>Are CVD risk scores calculated correctly?</td>
<td>Proportion of patients aged 40 years or older who have visited in the past 12 months who have all measurements required for calculating the risk score within 12 months of the most recent date of visit and have a documented risk score that is correct</td>
</tr>
<tr>
<td>Are patients being risk scored?</td>
<td>Proportion of eligible patients with a documented risk score</td>
</tr>
<tr>
<td>Are statins prescribed to the correct patients?</td>
<td>Proportion of eligible patients prescribed a statin</td>
</tr>
</tbody>
</table>
Table 1 continued

<table>
<thead>
<tr>
<th>Question</th>
<th>Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are statins prescribed correctly based on documented risk score?</td>
<td>Proportion of patients eligible based on documented risk score prescribed a statin</td>
</tr>
</tbody>
</table>
| Are patients with existing disease who do not require the calculation of a risk score to prescribe statins prescribed statins? | Proportion of patients with existing CVD prescribed a statin  
Proportion of people with diabetes older than 40 years prescribed statins |
| Is the blood pressure of high-risk patients controlled?                 | Proportion of high-risk patients (such as score ≥15% or diabetes and age older than 40 years) whose last two recorded blood pressure measurements were <130/80 mmHg, of which one was measured in the past 12 months |
| Is the blood pressure of low-risk patients controlled?                  | Proportion of low-risk patients (such as score <15%) whose last two recorded blood pressure measurements were <140/90 mmHg, of which one was measured in the past 12 months |
| Are patients with existing CVD prescribed basic medications to reduce risk? | Proportion of patients with existing CVD prescribed aspirin and blood pressure-lowering treatment |
| Is the blood glucose of patients with diabetes controlled?               | Proportion of patients with diabetes with glycaemic control as defined by the last two HbA₁c measurements                                   |
| Is the blood pressure of patients with hypertension controlled?          | Proportion of patients with confirmed hypertension whose systolic blood pressure is <140/90 mmHg at the last two visits, of which one was measured in the past 12 months |
| What is the prevalence of high blood pressure?                          | Proportion of people whose last two systolic blood pressure measurements are 140/90 mmHg or above, of which one was measured in the past 12 months |
Establish a practice standard

To adapt the core indicators to your context, you need to identify the practice standard against which you compare current practice. In many instances, this will be your established clinical guidelines that, for example, clearly define the diagnostic criteria for hypertension and hypertension control. You can use these standards to adapt the numerator and denominator of the core indicator set described above.

Further, you can calculate the core indicator set using multiple practice standards to compare. For example, you may choose to calculate the core indicators using information from your national clinical guidance and from the sample hypertension treatment protocols in the WHO HEARTS technical package (5).

Study design

The study design you choose will depend on your public health goal and/or the question your project seeks to answer.

Example goals

- To determine the prevalence of hypertension control and diabetes control
- To determine the impact of primary health care training on essential CVD interventions
- To provide a tool to help clinicians assess their own work and conduct quality improvement initiatives

Example study designs

- Cross-sectional descriptive study
- Before and after evaluation study or cluster randomized controlled trial
- Clinical audit

Fig. 1 and 2 show examples of two cluster randomized controlled trial study designs that used CVD ASSESS. These are simplified examples but illustrate where CVD ASSESS can be used – in these examples for baseline and follow-up quantitative data collection.

Identify the public health goal

CVD ASSESS can be used for multiple purposes. For example, it can be used at the health facility level to audit records and provide feedback to frontline clinicians for improving quality. It can also be used to determine nationally or regionally representative samples of clinical performance for monitoring and evaluation. Clearly defining the public health goal will help you to plan the use of CVD ASSESS and to determine key parameters such as the population to sample, the geographies to work with, the sample size, how data will be analysed and how the findings will be shared.

<table>
<thead>
<tr>
<th>Simplified question</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>How common is the problem?</td>
<td>Prevalence</td>
</tr>
<tr>
<td>To what degree is early detection worthwhile?</td>
<td>Screening</td>
</tr>
<tr>
<td>Is the diagnostic test accurate?</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>What will happen if we do nothing?</td>
<td>Prognosis</td>
</tr>
<tr>
<td>Does the intervention help?</td>
<td>Treatment</td>
</tr>
</tbody>
</table>

Human resources

Establish a steering committee

Consider establishing a steering committee to provide project oversight and management. When possible, the steering committee should strive to include representatives from primary health care (such as family physicians and nurses) to help to inform project development, knowledge dissemination and health-care improvement. Project teams need to ensure adequate technical support from those with experience in biostatistics, data analysis and appropriate research methods. The project management aspects the steering committee may consider coordinating include:

- project oversight and ethical standards;
- project management;
- reviewing and adapting CVD ASSESS to the local context;
- recruiting, commissioning and overseeing data collection and analysis;
- coordinating knowledge sharing and dissemination; and
- using data to advocate for changing policy and improving health care.

Data collection

You will need a team of people to collect data from patient records. Data collectors require training using the CVD ASSESS Data Collection Training Module but otherwise can comprise people with a range of skills and medical experience. It is recommended that data collectors have some knowledge of clinical medicine such that they can interpret information in patient records and make informed judgements about the data to extract. Examples of people suitable range from clinicians, including doctors and nurses, to medical students, medical residents or skilled research assistants. If data collectors have limited clinical medical experience (such as non-medical research assistants), the training should be adapted to provide additional topics such as common medical abbreviations, variation in units of measurement (such as mmol/L, mmol/mol and mg/dL) and common medications used for hypertension, diabetes and CVD.

Data analysis

You will need access to people trained in data analysis, which includes cleaning, coding, statistically analysing and communicating the data. WHO can assist in identifying this capacity if needed. Novices could be trained to do these tasks, but oversight from an experienced data scientist, statistician or epidemiologist is important. Any statistical analysis software can be used (such as SPSS or Stata), but we recommend using R (3) because it is free, open-source and has many freely available training courses (such as swirl (4)).

Source: Collins et al. (1)
Determining the sample size

Similar to the population sampling strategy, your sample size will depend on the overall goal of your project and may (such as a prevalence study or randomized controlled trial) or may not (such as a clinical audit by individual clinicians) be an important aspect of your methods.

However, there are clearly defined methods of determining a sample size based on the outcomes you are measuring, the difference you wish to detect, the probability of detecting that difference and the margin of error you are comfortable accepting. You should consult with a statistician when designing this part of your project.

Example from the Republic of Moldova

A sample size of 20 primary health care centres was chosen because it was seen as a good balance of allowing for variation in clinic geography and demography while still remaining feasible for the pilot implementation. Half the centres (n = 10) will be randomly allocated to the intervention arm and half (n = 10) to the control arm. Baseline data will be collected from both intervention and control clinics, ensuring that baseline data are collected before implementation occurs.

Source: Collins et al. (2).

Example from Tajikistan

A total of 400 patient records will be sampled at baseline and follow-up from each of the intervention and control arms (n = 800). The sample is based on a power calculation for the primary indicator (proportion of hypertensive patients whose blood pressure is controlled), estimated based on a WHO report that the control level in low- and middle-income countries is generally about 20–25%. A 10 percentage point difference between the intervention and control arms could be detected having 310 to 350 observations in each group using 0.05 type I error rate and 0.2 type II error rate. Sampling will be stratified by gender and selected in a 1:1 ratio of men to women (200 men and 200 women per arm). In the event that there are too few patients of a given gender, patients from the opposite gender will be substituted.

Source: Collins et al. (1).

Project protocol

Writing a project (or research) protocol before beginning data collection is best practice. This is to ensure scientific quality, reduce research waste, clearly define aims and objectives and outline ethical oversight. Although there are many forms that such protocols may take shape, reviewing existing published protocols using CVD ASSESS may be helpful (1,2).

Of course, your protocol may take many forms based on the aim of your project, from descriptive epidemiology to randomized controlled trials. Nevertheless, examples of some of the information you should consider including in your protocol include:

Population sample

Your population sample will depend on your public health goal, study design and overall research question. Including all patients of your target population in your study is typically not feasible. We therefore take samples of a given population so that we can make reasonable inferences about the population as a whole (Fig. 3). In an ideal world, we would include the entire target population, but this is simply not feasible. Random sampling is the gold standard method of sampling a predefined population in a way that increases external validity. The degree to which you can randomly sample a population depends on your context, expertise and resources.
Introduction
• CVD and primary health care in your country’s context
• Primary health care response to date
• Rationale for the project

Aim and objectives
• Identify your project aim
• Identify the objective(s) required to achieve this aim

Methods
• Study design
• (Intervention description)
• (Randomization technique)
• Sampling technique
• Indicators
• Data collection
  → Data collection instrument
  → Method of sampling patient records
  → Sample size
• Data analysis
  → Methods of analysis
  → Statistical analysis plan
• Patient and public involvement
• Ethical review

Strengths and limitations
Knowledge dissemination

References


The World Health Organization (WHO) is a specialized agency of the United Nations created in 1948 with the primary responsibility for international health matters and public health. The WHO Regional Office for Europe is one of six regional offices throughout the world, each with its own programme geared to the particular health conditions of the countries it serves.

Member States

Albania
Andorra
Armenia
Austria
Azerbaijan
Belarus
Belgium
Bosnia and Herzegovina
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Georgia
Germany
Greece
Hungary
Iceland
Ireland
Israel
Italy
Kazakhstan
Kyrgyzstan
Latvia
Lithuania
Luxembourg
Malta
Monaco
Montenegro
Netherlands
North Macedonia
Norway
Poland
Portugal
Republic of Moldova
Romania
Russian Federation
San Marino
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Tajikistan
Turkey
Turkmenistan
Ukraine
United Kingdom
Uzbekistan